- Home
- AIN vs AUPH Comparison
AIN vs AUPH Comparison
Compare AIN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIN
- AUPH
- Stock Information
- Founded
- AIN 1895
- AUPH 1993
- Country
- AIN United States
- AUPH Canada
- Employees
- AIN N/A
- AUPH N/A
- Industry
- AIN Textiles
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- AIN Consumer Discretionary
- AUPH Health Care
- Exchange
- AIN Nasdaq
- AUPH Nasdaq
- Market Cap
- AIN 1.7B
- AUPH 1.6B
- IPO Year
- AIN 1987
- AUPH 1999
- Fundamental
- Price
- AIN $59.25
- AUPH $12.54
- Analyst Decision
- AIN Hold
- AUPH Strong Buy
- Analyst Count
- AIN 4
- AUPH 2
- Target Price
- AIN $65.50
- AUPH $13.00
- AVG Volume (30 Days)
- AIN 268.7K
- AUPH 1.2M
- Earning Date
- AIN 11-05-2025
- AUPH 11-10-2025
- Dividend Yield
- AIN 1.82%
- AUPH N/A
- EPS Growth
- AIN N/A
- AUPH N/A
- EPS
- AIN 2.01
- AUPH 0.42
- Revenue
- AIN $1,185,464,000.00
- AUPH $260,111,000.00
- Revenue This Year
- AIN N/A
- AUPH $17.33
- Revenue Next Year
- AIN $4.19
- AUPH $14.31
- P/E Ratio
- AIN $29.42
- AUPH $30.05
- Revenue Growth
- AIN N/A
- AUPH 25.59
- 52 Week Low
- AIN $50.60
- AUPH $6.55
- 52 Week High
- AIN $88.13
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- AIN 56.60
- AUPH 60.86
- Support Level
- AIN $57.17
- AUPH $11.48
- Resistance Level
- AIN $61.21
- AUPH $12.70
- Average True Range (ATR)
- AIN 1.71
- AUPH 0.34
- MACD
- AIN 0.67
- AUPH 0.13
- Stochastic Oscillator
- AIN 73.99
- AUPH 89.64
About AIN Albany International Corporation
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.